title: Low dose versus high dose stavudine for treating people with HIV infection.
abstract: BACKGROUND
  Stavudine remains a component of combination antiretroviral therapy (ART) in resource-constrained countries due to its relatively low cost despite the WHO recommendation for its phasing out as a strategy to reduce stavudine associated toxicities. Where stavudine is still in use, it is recommended at a dose lower than the standard dose in order to reduce stavudine related toxicity.
  
  
  OBJECTIVE
  To compare the safety and virologic efficacy of low dose versus high dose stavudine for treating HIV-1 infection.
  
  
  METHODS
  The comprehensive search strategy developed by the Cochrane HIV/AIDS Review Group was used to identify randomised controlled trials that compared the use of low dose versus high dose stavudine. The last search was conducted in February 2014 and the searches covered the period 1996 to 2014.
  
  
  METHODS
  Randomised controlled trials comparing the use of low dose and high dose stavudine as part of ART combination therapy for treating adults.
  
  
  METHODS
  Two reviewers independently selected eligible trials, assessed methodological quality of the included studies and completed data extraction and analysis.
  
  
  RESULTS
  The search identified 3952 abstracts which were scanned for relevance. Three trials met the inclusion criteria (Milinkovic 2007; McComsey 2008; Sanchez-Conde 2005). All three trials were conducted in developed countries, participants were ART experienced and all had sustained virologic suppression at baseline. A total of 157 participants were recruited to the trials. Sample sizes ranged from 24 to 92 and more than 79% of participants were male.The studies were at a high risk of selection, performance/detection and selective outcome reporting biases. Some baseline characteristics differed among the groups, including triglyceride levels in two studies and body mass index in one study. In light of variation in the design and follow-up of the study results, no meta-analysis was performed and the results of single studies are presented. There was no significant difference in virologic suppression in the included studies (Milinkovic 2007; McComsey 2008; Sanchez-Conde 2005); Risk Ratio (RR) 1.09 (95% CI: 0.93 to 1.28), 0.94 (95% CI:0.59 to 1.50) and 1.03 (95% CI: 0.90 to 1.18) respectively. Symptomatic hyperlactatemia was seen in the high dose arm of the Milinkovic 2007 study; RR 0.21 (95% CI: 0.01 to 4.66), in no participants in the McComsey 2008 trial and not reported on in the Sanchez-Conde 2005 trial. McComsey 2008 and Milinkovic 2007 demonstrated a reduction in bone mineral density (BMD), reduction in limb fat and an increase in triglycerides in the high dose arms. The studies did not indicate that any participants discontinued treatment due to adverse events.
  
  
  CONCLUSIONS
  This systematic review identified only three small trials that evaluated virologic efficacy and safety of high dose versus low dose stavudine. All three trials were conducted in developed countries and none reported from developing countries yet stavudine remains a component of ART combination therapy in many developing countries. It was not possible to perform a meta-analysis on these trails. Individual results from the trials were imprecise and have not identified a clear advantage in virologic efficacy or safety between low and high dose stavudine. Furthermore, enrolled participants were treatment experienced with sustained virologic suppression and so existing data cannot be generalized to settings where stavudine is currently used in ART naive patients with high viral loads. Stavudine dose reduction trials in ART naive patients, in developing countries where stavudine is still being used are warranted as the phasing out of stavudine that is recommended by WHO may not be immediately universally feasible.
authors: Nelson R Mandela School of Medicine, Durban, KwaZulu-Natal, South Africa.
authors: Nombulelo
authors: N
authors: Magula
authors: Martin
authors: M
authors: Dedicoat
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003906:Developing Countries; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1; D006801:Humans; D008297:Male; D016032:Randomized Controlled Trials as Topic; D018119:Stavudine / Q000008:administration & dosage* / Q000009:adverse effects; D019562:Viral Load / Q000187:drug effects
chemical_list: D019380:Anti-HIV Agents; D018119:Stavudine
references: J Infect Dis. 1995 Mar;171 Suppl 2:S118-22
references: 7861016
references: Muscle Nerve. 2010 May;41(5):599-606
references: 20229576
references: AIDS. 2000 Jul 7;14(10):1375-82
references: 10930152
references: N Engl J Med. 2006 Jan 19;354(3):251-60
references: 16421366
references: S Afr Med J. 2006 Aug;96(8):722-4
references: 17019496
references: Pharmacogenet Genomics. 2006 Mar;16(3):191-8
references: 16495778
references: JAMA. 2004 Jul 14;292(2):191-201
references: 15249568
references: Nat Med. 1995 May;1(5):417-22
references: 7585087
references: S Afr Med J. 2008 Oct;98(10):795-800
references: 19115757
references: J Infect Dis. 1993 Jan;167(1):21-9
references: 8093363
references: PLoS One. 2011;6(11):e28112
references: 22132226
references: AIDS. 1998 Oct 1;12(14):1735-44
references: 9792373
references: Clin Ther. 2000 Jun;22(6):685-708
references: 10929917
references: J Infect Dis. 1995 Mar;171 Suppl 2:S131-9
references: 7861018
references: HIV Clin Trials. 2005 Jul-Aug;6(4):197-202
references: 16214736
references: HIV Med. 2013 Apr;14(4):217-25
references: 23036096
references: Clin Infect Dis. 2008 Apr 15;46(8):1290-6
references: 18444869
references: Antimicrob Agents Chemother. 2002 Mar;46(3):716-23
references: 11850253
references: Diabetes Care. 2008 Jun;31(6):1224-9
references: 18268071
references: Antivir Ther. 2007;12(3):407-15
references: 17591031
references: Expert Opin Drug Saf. 2008 May;7(3):283-93
references: 18462186
references: Lancet. 1999 Sep 25;354(9184):1112-5
references: 10509516
references: Lancet. 2006 Aug 5;368(9534):505-10
references: 16890837
references: J Acquir Immune Defic Syndr. 1999 Sep 1;22(1):39-48
references: 10534145
references: Cochrane Database Syst Rev. 2015 Jan 28;1:CD007497
references: 25627012
references: J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):304-11
references: 18398971
references: Pharmacoepidemiol Drug Saf. 2002 Sep;11(6):439-46
references: 12426927
references: Expert Opin Pharmacother. 2007 Apr;8(5):679-88
references: 17376022